SH2D1A is altered in 0.50% of all cancers with lung adenocarcinoma, high grade ovarian serous adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and cutaneous melanoma having the greatest prevalence of alterations .
The most common alterations in SH2D1A are SH2D1A Loss (0.16%), SH2D1A Amplification (0.05%), SH2D1A V40M (0.09%), SH2D1A R75I (0.01%), and SH2D1A R78W (0.01%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.